Abbott FreeStyle Libre 3 reader is now available, covered by Medicare

The FreeStyle Libre 3 reader with the sensor and smartphone. [Image courtesy of Abbott]Abbott (NYSE: ABT) + has made its FreeStyle Libre 3 reader available in the U.S., enabling people on Medicare to access the system.

The FreeStyle Libre 3 reader pairs with the company’s latest continuous glucose monitor (CGM) sensor, cleared by the FDA last year. The addressable market for the sensor keeps growing, with massive coverage expansions all around the globe.

A Medicare coverage update kicked in this past spring, expanding access to the sensor. This modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Abbott is pulling its Trifecta valves off the market

The Trifecta GT heart valve [Image courtesy of Abbott]Abbott (NYSE: ABT) + announced today that it is withdrawing its Trifecta family of heart valves from worldwide markets.

The market withdrawal comes more than five months after Abbott and the FDA told health providers that the valves could deteriorate early.

In a statement shared with MassDevice, the company said: “Abbott has decided to withdraw and discontinue its Trifecta family of valves to focus on its next-generation tissue valves that maximize possibilities for lifetime management of valvular heart disease.”

In a letter dated today and shared by the FDA, the company told U.S. health providers that it would collect its unused consigned inventory and assist in the returns of any customer-owned inventory.

The company added in its shared statement: “Abbott is initiating inventory-related activities worldwide for unused Trifecta and Trif…

Read more
  • 0

Abbott has a serious recall involving its Amplatzer delivery sheath

The Amplatzer steerable delivery sheath [Image courtesy of Abbott]The FDA today said an Abbott recall involving its Amplatzer steerable delivery sheath is Class I, its most serious level.

Launched in the U.S. in April 2022, the Amplatzer sheath delivers Abbott’s Amplatzer Amulet left atrial appendage occluder. Competing against Boston Scientific’s Watchman, Amplatzer Amulet provides complete occlusion in order to reduce the risk of ischemic stroke among people with atrial fibrillation.

Abbott, in June, initiated a recall of model No. ASDS-14F-075 of the sheath — 672 devices distributed in the U.S. between Oct. 4, 2022, and Feb. 22, 2023 — because there is an increased risk for the introduction of air bubbles (air emboli) into patients who have procedures with this device, according to the FDA.

The company reports 26 incidents, 16 injuries, and no deaths related to this issue.

Abbott is asking health providers to return any remaining unuse…

Read more
  • 0

Abbott Diabetes business booms in Q2, company set to submit new sensor in U.S. this year

The FreeStyle Libre 3 continuous glucose monitor. [Image courtesy of Abbott]Abbott (NYSE:ABT) today shared a number of positive updates on its Diabetes business as part of its second-quarter earnings report.

The medtech giant’s Diabetes unit brought in sales of $1.4 billion in the quarter, marking 19.4% growth year-over-year.

Its FreeStyle Libre continuous glucose monitors (CGMs) continue to drive growth as CEO Robert Ford projected earlier this year. The addressable market for the sensor keeps growing, with massive coverage expansions all around the globe. Medicare’s coverage update kicked in this past spring. This modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.

Last month, France authorized reimbursement to include all people who use basal insulin as part of their diabetes management.

“This achievement was a direct result of the unique value proposition that L…

Read more
  • 0

Abbott beats The Street in Q2 — ups sales growth forecast

Abbott (NYSE: ABT) + today announced second-quarter results that beat the consensus of Wall Street analysts — boosting its full-year organic sales growth forecast.

The company has now seen two quarters in a row of double-digit organic sales growth in its underlying business. Even as COVID-19 test sales continue to decline and hammer overall revenue, Abbott officials are betting on a productive, innovative pipeline to build momentum — especially in its Medical Device business. CEO Robert Ford said underlying demand trends continue to improve. “Healthcare systems around the world have improved the supply of healthcare services,” Ford told analysts today.

Ford concluded: “Momentum is building. We’re well-positioned heading into the second half of this year and heading into next year.”

Investors reacted by sending ABT shares up more than 4% to $112.17 apiece in morning trading. MassDevi…

Read more
  • 0

July 2023 edition: Life-saving LVADs, supplier innovations and AI breakthroughs



LVADs save lives: So why aren’t more available?

What’s new in 3D printing: medical devices, research, innovation, automation and partnerships

AI breakthroughs in medtech: 7 ways to enhance healthcare

Life-saving LVADs, supplier innovations and AI breakthroughs

Kyree Miller recalls the day his heart stopped beating.

“I remember the entire room going white,” he said. “And I actually turned over on my side and I said, ‘Tell my mom I love her.’”

A couple of weeks later, the heart failure patient — who was only in his 20s at the time — received his first left ventricular assist device (LVAD) implant while he waited for a heart transplant. One year passed, then two, then three. Finally, after surviving on LVAD technology for seven years, his new heart came.

“When you get your transplant, there’s a whole new energy that you get. … But I can honestly say there was a whole new energy that I got when I had my LVAD,” Miller said.

…
Read more
  • 0

Abbott wins FDA nod for first dual-chamber leadless pacemaker

The Aveir dual-chamber leadless pacemaker. [Image courtesy of Abbott]Abbott (NYSE: ABT) + announced today that it received FDA approval for its Aveir dual-chamber leadless pacemaker system.

The approval marks the first such nod for a dual-chamber leadless pacing system for treating abnormal or slow heart rhythms. According to Abbott, more than 80% of people who need a pacemaker require pacing in two chambers of the heart — the right atrium and right ventricle.

This approval “significantly increases access” to the pacing technology for millions in the U.S., the company said in a news release.

Approval follows clinical data shared in May that supported Aveir DR. The data came from the company’s large-scale FDA investigational device exemption (IDE) study. Results included a 98.3% implant success rate and more than 97% of patients presenting successful atrio-ventricular synchrony. Abbott said the data sugg…

Read more
  • 0

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]

As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a number of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came …

Read more
  • 0

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a range of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came out of Senseonics, Sernova, Bigfoot Biomedical and more.<…

Read more
  • 0

CAPA doesn’t have to be a four-letter word, Medtronic Quality/Regulatory Director Kathryn Merrill says

[Illustration by Vitalii Vodolazskyi via Adobe Stock]

Medtronic Quality/Regulatory Program Director Kathryn Merrill is a problem-solver’s problem solver.

Right now, the problem she wants to solve is the way device manufacturers approach corrective and preventative actions — CAPA, an abbreviation that can trigger an avalanche of documentation and headaches for medtech engineers.

For five years, Merrill’s been part of a Medical Device Innovation Consortium (MDIC) team developing a new approach to CAPA, stemming out of conversations across the medtech industry and beyond. The goal was to implement improvements in months instead of years and allow teams to be more proactive.

“I’ve been at Medtronic for 26 years and very often we’d say, ‘Hey, I think we’re making this more complicated than it needs to be,'” said Merrill, who is lead co-author of MDIC̵…

Read more
  • 0

Abbott, ADA partner on therapeutic nutrition program for people with diabetes

The FreeStyle Libre 3 continuous glucose monitor. [Image courtesy of Abbott]Abbott (NYSE: ABT) + and the American Diabetes Association (ADA) announced a collaboration to improve nutrition for people with diabetes.

The duo aims to help better understand how diabetes technology, like continuous glucose monitoring (CGM), can help. They hope to aid people with diabetes make more informed decisions about their food and activity.

Abbott develops a family of CGMs, the latest being the FreeStyle Libre 3. The company said that, over time, data from CGMs helps people with diabetes learn patterns and create a nutritional plan. That plan can help provide steady glucose levels and the potential for improved clinical outcomes, like lower A1C.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Insulet makes progress on integrating Omnipod 5 with Abbott FreeStyle Libre 2

The Insulet Omnipod 5 [Photo courtesy of Insulet]Insulet (Nasdaq:PODD) today announced a duo of updates related to its Omnipod 5 system that includes a significant integration development.

The company submitted an updated mobile application for regulatory clearance and aims to integrate Omnipod 5 with the Abbott FreeStyle Libre 2.

Acton, Massachusetts-based Insulet plans to discuss a range of developments related to its product line in the coming days at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego. Presentations include real-world evidence of improved outcomes and optimization using the Omnipod 5 automated insulin delivery system.

News of these developments follows the UK launch of Omnipod 5 earlier this week.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0